COTI-2 HCl | CAS#1204956-74-0 | P53 gene modulator | AKT2 inhibitor

MedKoo Cat#: 125329 | Name: COTI-2 HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

COTI-2 is an P53 gene modulator and AKT2 inhibitor. COTI-2 is a third-generation thiosemicarbazone with selective anticancer activity, particularly in TP53-mutant tumors. In vitro studies have demonstrated that COTI-2 exhibits potent cytotoxicity across various cancer cell lines, including ovarian, head and neck, and colorectal cancers, with IC₅₀ values in the low micromolar to nanomolar range. Mechanistically, it restores mutant p53 to a wild-type conformation, leading to reactivation of p53-dependent apoptosis and cell cycle arrest. Additionally, COTI-2 inhibits the PI3K/AKT/mTOR pathway, contributing to its antiproliferative effects. These dual mechanisms of action make COTI-2 a promising candidate for targeted cancer therapy.

Chemical Structure

COTI-2 HCl

CAS#1204956-74-0 (HCl)

Theoretical Analysis

MedKoo Cat#: 125329

Name: COTI-2 HCl

CAS#: 1204956-74-0 (HCl)

Chemical Formula: C19H23ClN6S

Exact Mass: 402.1400

Molecular Weight: 402.95

Elemental Analysis: C, 56.64; H, 5.75; Cl, 8.80; N, 20.86; S, 7.96

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

1204956-74-0 (HCl) 1039455-84-9 (free base)

Synonym

1204956-74-0; COTI-2 hydrochloride; UNII-52508056ID; 52508056ID

IUPAC/Chemical Name

(E)-N'-(6,7-dihydroquinolin-8(5H)-ylidene)-4-(pyridin-2-yl)piperazine-1-carbothiohydrazide hydrochloride

InChi Key

AJEFZRURUAFCRQ-YHLMHSEJSA-N

InChi Code

InChI=1S/C19H22N6S.ClH/c26-19(23-22-16-7-3-5-15-6-4-10-21-18(15)16)25-13-11-24(12-14-25)17-8-1-2-9-20-17;/h1-2,4,6,8-10H,3,5,7,11-14H2,(H,23,26);1H/b22-16+;

SMILES Code

Cl.S=C(N\N=C1/CCCC2=C1N=CC=C2)N3CCN(CC3)C4=CC=CC=N4

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 402.95 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Maleki Vareki S, Salim KY, Danter WR, Koropatnick J. Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines. PLoS One. 2018 Jan 24;13(1):e0191766. doi: 10.1371/journal.pone.0191766. eCollection 2018. PubMed PMID: 29364966. 2: Heffeter P, Pape VFS, Enyedy EA, Keppler BK, Szakas G, Kowol CR. Anticancer thiosemicarbazones: chemical properties, interaction with iron metabolism, and resistance development. Antioxid Redox Signal. 2018 Jan 15. doi: 10.1089/ars.2017.7487. [Epub ahead of print] PubMed PMID: 29334758. 3: Salim KY, Vareki SM, Danter WR, San-Marina S, Koropatnick J. Correction: COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo. Oncotarget. 2017 Sep 1;8(36):60724. doi: 10.18632/oncotarget.20600. eCollection 2017 Sep 1. PubMed PMID: 29062467; PubMed Central PMCID: PMC5601175. 4: Duffy MJ, Synnott NC, Crown J. Mutant p53 as a target for cancer treatment. Eur J Cancer. 2017 Sep;83:258-265. doi: 10.1016/j.ejca.2017.06.023. Epub 2017 Jul 28. Review. PubMed PMID: 28756138. 5: Salim KY, Maleki Vareki S, Danter WR, Koropatnick J. COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo. Oncotarget. 2016 Jul 5;7(27):41363-41379. doi: 10.18632/oncotarget.9133. Erratum in: Oncotarget. 2017 Sep 1;8(36):60724. PubMed PMID: 27150056; PubMed Central PMCID: PMC5173065.